caa a22 4500 606180095 CHVBK 20210128100804.0 cr unu---uuuuu 210128e20150501xx s 000 0 eng 10.1007/s11136-014-0842-1 doi (NATIONALLICENCE)springer-10.1007/s11136-014-0842-1 Insomnia, hypnotic use, and health-related quality of life in a nationally representative sample [Elektronische Daten] [Julieta Scalo, Pooja Desai, Karen Rascati] Purpose: To assess health-related quality of life (HRQoL) associated with insomnia and prescription hypnotic use. Methods: Primary outcomes were mental component summary (MCS) and physical component summary (PCS) scores from the 12-item Short-Form Health Survey. Using multiple regression, subjects in the 2005 through 2009 Medical Expenditure Panel Survey with diagnosed insomnia were compared against those without that diagnosis. Among subjects with diagnosed insomnia, users of prescription hypnotics were compared against nonusers. Results: Of 104,274 adults, 1.3% (n=1,401) had an insomnia diagnosis. Of those, 45.6% (n=639) used prescription hypnotics. For subjects with insomnia, mean PCS and MCS scores were 9.2 and 7.0 points lower (p<0.001), respectively. After controlling for demographic and clinical covariates, differences remained significant (PCS:5.1; MCS:6.2; p<0.001). Among subjects with insomnia, HRQoL scores were not different between prescription hypnotic users (n=639) and nonusers (n=762). Analysis by drug class revealed lower PCS scores (difference: 7.5, p<0.001) with benzodiazepine use (n=129) versus benzodiazepine receptor agonist use (n=493), but the adjusted difference was not significant (difference: 3.8, p=.018). Conclusions: Diagnosed insomnia was associated with consistent decreases in both physical and mental HRQoL scores, regardless of whether prescription hypnotics were used. Benzodiazepine use may be associated with a further decrease in physical HRQoL scores. Although limited by its retrospective design, this study provides a first look at real-world hypnotic use outcomes at a national level. Important next steps include studies with patients serving as their own controls, and further evaluation of the sensitivity of HRQoL instruments to the effects of insomnia treatments. Springer International Publishing Switzerland, 2014 Health-related quality of life nationallicence Insomnia nationallicence Sleep nationallicence Hypnotic nationallicence SF-12 nationallicence MEPS nationallicence Scalo Julieta College of Pharmacy, The University of Texas at Austin, 2409 University Avenue A1930, 78712, Austin, TX, USA aut Desai Pooja College of Pharmacy, The University of Texas at Austin, 2409 University Avenue A1930, 78712, Austin, TX, USA aut Rascati Karen College of Pharmacy, The University of Texas at Austin, 2409 University Avenue A1930, 78712, Austin, TX, USA aut Quality of Life Research Springer International Publishing 24/5(2015-05-01), 1223-1233 0962-9343 24:5<1223 2015 24 11136 https://doi.org/10.1007/s11136-014-0842-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11136-014-0842-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Scalo Julieta College of Pharmacy, The University of Texas at Austin, 2409 University Avenue A1930, 78712, Austin, TX, USA aut NATIONALLICENCE 700 1- Desai Pooja College of Pharmacy, The University of Texas at Austin, 2409 University Avenue A1930, 78712, Austin, TX, USA aut NATIONALLICENCE 700 1- Rascati Karen College of Pharmacy, The University of Texas at Austin, 2409 University Avenue A1930, 78712, Austin, TX, USA aut NATIONALLICENCE 773 0- Quality of Life Research Springer International Publishing 24/5(2015-05-01), 1223-1233 0962-9343 24:5<1223 2015 24 11136